{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:11:59Z","timestamp":1793261519408,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jacc.2023.04.019","type":"journal-article","created":{"date-parts":[[2023,5,21]],"date-time":"2023-05-21T05:14:13Z","timestamp":1684646053000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":173,"title":["Angiotensin-Neprilysin Inhibition in\u00a0Patients With Mildly Reduced or\u00a0Preserved Ejection Fraction and\u00a0Worsening Heart\u00a0Failure"],"prefix":"10.1016","volume":"82","author":[{"given":"Robert J.","family":"Mentz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan H.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Lepage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samiha","family":"Sarwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall C.","family":"Starling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Velazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin M.","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Zieroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Braunwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.jacc.2023.04.019_bib1","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.jacc.2023.04.019_bib2","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.jacc.2023.04.019_bib3","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.cardfail.2021.04.023","article-title":"JCS\/JHFS 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure","volume":"27","author":"Tsutsui","year":"2021","journal-title":"J\u00a0Card Fail"},{"issue":"36","key":"10.1016\/j.jacc.2023.04.019_bib4","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jacc.2023.04.019_bib5","doi-asserted-by":"crossref","first-page":"212","DOI":"10.5694\/mja2.51656","article-title":"Consensus statement on the current pharmacological prevention and management of heart failure","volume":"217","author":"Sindone","year":"2022","journal-title":"Med J Aust"},{"issue":"3","key":"10.1016\/j.jacc.2023.04.019_bib6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jacc.2019.11.003","article-title":"Prior heart failure hospitalization, clinical outcomes, and response to sacubitril\/valsartan compared with valsartan in HFpEF","volume":"75","author":"Vaduganathan","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jacc.2023.04.019_bib7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jacc.2022.11.023","article-title":"Worsening heart failure: nomenclature, epidemiology, and future directions: JACC review topic of the week","volume":"81","author":"Greene","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jacc.2023.04.019_bib8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrcardio.2015.14","article-title":"The vulnerable phase after hospitalization for heart failure","volume":"12","author":"Greene","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2023.04.019_bib9","doi-asserted-by":"crossref","unstructured":"Mentz RJ, Ward JH, Hernandez AF, et\u00a0al. Rationale, design and baseline characteristics of the PARAGLIDE-HF Trial: sacubitril\/valsartan versus valsartan in HFmrEF and HFpEF with a worsening heart failure Event. J Card Fail. Published online February 14, 2023. https:\/\/doi.org\/10.1016\/j.cardfail.2023.02.001","DOI":"10.1016\/j.cardfail.2023.02.001"},{"issue":"6","key":"10.1016\/j.jacc.2023.04.019_bib10","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jacc.2023.04.019_bib11","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/eurheartj\/ehr352","article-title":"The\u00a0win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities","volume":"33","author":"Pocock","year":"2012","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jacc.2023.04.019_bib12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/1467-9868.00259","article-title":"Semiparametric regression for the mean and rate functions of recurrent events","volume":"62","author":"Lin","year":"2000","journal-title":"J\u00a0R Stat Soc Series B Stat Methodol"},{"issue":"9851","key":"10.1016\/j.jacc.2023.04.019_bib13","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jacc.2023.04.019_bib14","first-page":"372","article-title":"Effects of sacubitril\/valsartan on n-terminal pro-B-type natriuretic peptide in heart failure with preserved ejection fraction","volume":"8","author":"Cunningham","year":"2020","journal-title":"J\u00a0Am Coll Cardiol HF"},{"issue":"7","key":"10.1016\/j.jacc.2023.04.019_bib15","first-page":"513","article-title":"Racial differences in natriuretic peptide levels: the Dallas Heart Study","volume":"3","author":"Gupta","year":"2015","journal-title":"J\u00a0Am Coll Cardiol HF"},{"issue":"10","key":"10.1016\/j.jacc.2023.04.019_bib16","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1161\/CIRCULATIONAHA.120.046374","article-title":"Racial differences in serial NT-proBNP levels in heart failure management: insights from the GUIDE-IT Trial","volume":"142","author":"Parcha","year":"2020","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.jacc.2023.04.019_bib17","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1002\/ejhf.2638","article-title":"Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON-HF trial","volume":"24","author":"Chatur","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.jacc.2023.04.019_bib18","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009340","article-title":"Targeting preload in heart failure: splanchnic nerve blockade and beyond","volume":"15","author":"Fudim","year":"2022","journal-title":"Circ Heart Fail"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109723054293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109723054293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:56:53Z","timestamp":1760018213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109723054293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0735109723054293"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2023.04.019","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742654735.793599877","asserted-by":"object"}]},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiotensin-Neprilysin Inhibition in\u00a0Patients With Mildly Reduced or\u00a0Preserved Ejection Fraction and\u00a0Worsening Heart\u00a0Failure","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2023.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}